edgen-logoBeta

Chat with Ed

Invest

Brief

Desk
Others

News

Discover

Portfolio
Missions
Follow our

Join our

EN
Back


healthcare: pharmaNews

For youMarketsEconomyTech & AICryptoEnergyHealthcareHK & ChinaFinance

Pharma

Biotech

Health Services

Medical Devices

Ionis wins FDA approval for Tryngolza as first sHTG treatment to cut pancreatitis risk

Ionis wins FDA approval for Tryngolza as first sHTG treatment to cut pancreatitis risk

Jun 24 2026, 18:53
Pfizer's Ibrance regimen cuts progression risk 24% in new FDA nod

Pfizer's Ibrance regimen cuts progression risk 24% in new FDA nod

Jun 24 2026, 18:26
Viking Therapeutics starts Phase 1 trial of obesity drug VK3019

Viking Therapeutics starts Phase 1 trial of obesity drug VK3019

Jun 24 2026, 11:24
Takeda appoints Julie Kim as CEO at 150th annual shareholder meeting

Takeda appoints Julie Kim as CEO at 150th annual shareholder meeting

Jun 24 2026, 09:06
Abbisko expands Lilly drug deal to $1.9 billion across multiple targets

Abbisko expands Lilly drug deal to $1.9 billion across multiple targets

Jun 24 2026, 01:49
Eli Lilly targets 2027 European weight-loss pill launch under Trump pricing rules

Eli Lilly targets 2027 European weight-loss pill launch under Trump pricing rules

Jun 23 2026, 16:36
Pfizer's sigvotatug vedotin misses Phase 3 survival endpoint in lung cancer

Pfizer's sigvotatug vedotin misses Phase 3 survival endpoint in lung cancer

Jun 22 2026, 20:59
Praxis Precision Medicines gains 4% on FDA breakthrough therapy for elsunersen

Praxis Precision Medicines gains 4% on FDA breakthrough therapy for elsunersen

Jun 22 2026, 18:05
Definium shares surge 55% on positive Phase 3 depression trial

Definium shares surge 55% on positive Phase 3 depression trial

Jun 22 2026, 17:58
Novo Nordisk oral Wegovy pill runs 3x ahead of rival Zepbound

Novo Nordisk oral Wegovy pill runs 3x ahead of rival Zepbound

Jun 22 2026, 12:57
Achieve Life Sciences gets FDA Complete Response Letter, targets Q4 2026 refiling

Achieve Life Sciences gets FDA Complete Response Letter, targets Q4 2026 refiling

Jun 22 2026, 12:55
MoonLake sonelokimab hits 67% response rate in Phase 3 HS trial at 52 weeks

MoonLake sonelokimab hits 67% response rate in Phase 3 HS trial at 52 weeks

Jun 21 2026, 21:22
Novo Nordisk Wegovy pill hits 3 million prescriptions as oral GLP-1 gains traction

Novo Nordisk Wegovy pill hits 3 million prescriptions as oral GLP-1 gains traction

Jun 20 2026, 16:52
Vertex leads Eli Lilly in $80B non-opioid pain market race

Vertex leads Eli Lilly in $80B non-opioid pain market race

Jun 20 2026, 06:55
WuXi Biologics passes fourth EMA GMP inspection, enabling 19 EU products

WuXi Biologics passes fourth EMA GMP inspection, enabling 19 EU products

Jun 18 2026, 05:11
FDA approves first generic of Roche's Xofluza as flu competition looms

FDA approves first generic of Roche's Xofluza as flu competition looms

Jun 17 2026, 22:44
Gilead seeks FDA nod for weekly oral Yeztugo with February 2027 target

Gilead seeks FDA nod for weekly oral Yeztugo with February 2027 target

Jun 16 2026, 19:37
Novo Nordisk hackers steal 1.3TB of data after $25M extortion fails

Novo Nordisk hackers steal 1.3TB of data after $25M extortion fails

Jun 16 2026, 18:07
Mirum, Incyte's zilurgisertib cuts FOP lesions 81% as FDA starts Priority Review

Mirum, Incyte's zilurgisertib cuts FOP lesions 81% as FDA starts Priority Review

Jun 16 2026, 09:30
Sanofi wins FDA nod for Tzield in stage 3 diabetes for children

Sanofi wins FDA nod for Tzield in stage 3 diabetes for children

Jun 15 2026, 17:28

Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Crypto Comparison
Home Page
Markets
US Stocks
HK Stocks
Crypto
News
Analyst Moves
Market Moves
Hong Kong IPO
Earnings
AI & Technology
Macro & Policy
Terms of UsePrivacy PolicySitemap
© 2026 Edgen Powered byedgen-logo